Literature DB >> 17100615

TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy.

K Hoebe1, Z Jiang, P Georgel, K Tabeta, E Janssen, X Du, B Beutler.   

Abstract

The identification of the TLRs as key sensors of microbial infection has presented a series of new targets for drug development. The TLRs are linked to the most powerful inflammatory pathways in mammals. The question arises from the start: do we wish to stimulate TLR signaling in order to eradicate specific infections and/or neoplastic diseases? Or do we wish to block TLR signaling to treat inflammatory diseases? If we accept that it would be useful to modulate TLR signaling, the next step is to identify the correct molecular target(s) for the task. Perhaps it might even be possible to exercise selectivity, modulating some aspects of TLR signaling and not others. Classical and reverse genetic analyses offer insight into the possibilities that exist, and point to specific checkpoints within signaling pathways at which modulation might normally be imposed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100615     DOI: 10.2174/138161206778743466

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  24 in total

1.  Spatiotemporal inhibition of innate immunity signaling by the Tbc1d23 RAB-GAP.

Authors:  Lesly De Arras; Ivana V Yang; Brad Lackford; David W H Riches; Rytis Prekeris; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

2.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

3.  A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-α release from mouse JAWS II dendritic cells.

Authors:  Shanjana Awasthi; Kevin Brown; Catherine King; Vibhudutta Awasthi; Rajkumar Bondugula
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

Review 4.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

Review 6.  Toll-like receptors in skin infections and inflammatory diseases.

Authors:  Yuping Lai; Richard L Gallo
Journal:  Infect Disord Drug Targets       Date:  2008-09

7.  Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal.

Authors:  Sung-Chun Tang; Justin D Lathia; Pradeep K Selvaraj; Dong-Gyu Jo; Mohamed R Mughal; Aiwu Cheng; Dominic A Siler; William R Markesbery; Thiruma V Arumugam; Mark P Mattson
Journal:  Exp Neurol       Date:  2008-05-29       Impact factor: 5.330

Review 8.  Identifying novel spatiotemporal regulators of innate immunity.

Authors:  Francisco Victorino; Scott Alper
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

9.  Identification of innate immunity genes and pathways using a comparative genomics approach.

Authors:  Scott Alper; Rebecca Laws; Brad Lackford; Windy A Boyd; Paul Dunlap; Jonathan H Freedman; David A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-07       Impact factor: 11.205

10.  Identification of potential pathway mediation targets in Toll-like receptor signaling.

Authors:  Fan Li; Ines Thiele; Neema Jamshidi; Bernhard Ø Palsson
Journal:  PLoS Comput Biol       Date:  2009-02-20       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.